
AstraZeneca Imfinzi recommended for approval in EU for adults with muscle-invasive bladder cancer
Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and …